Menu
News
Recent news
Santersus AG today announced the successful completion of its Series A financing, led by Norcliffe, a UK life sciences fund with participation from Terumo Ventures. The financing will support the advancement of Santersus’ NucleoCapture™ into pivotal clinical development while accelerating progress across Santersus’ broader pipeline.
September 13, 2025
Santersus AG congratulates its alliance partner OrganOx Ltd on the company’s acquisition by Terumo Corporation in a transaction valued at up to $1.5 billion — a major milestone in the evolution of global transplant technologies.
August 27, 2025
Santersus AG today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its NucleoCapture™ blood purification technology for the treatment of severe, treatment-refractory systemic lupus erythematosus (SLE). This marks the second Breakthrough Device Designation awarded to NucleoCapture™, following earlier recognition for the treatment of sepsis.
Santersus AG presented its groundbreaking NucleoCapture technology at the prestigious BRAIN Conference 2024 in London. The event brought together global experts to advance neurovascular research and discuss cutting-edge developments in brain health.